Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Changes in the AML treatment landscape

Richard Stone • 18 Mar 2018
EBMT 2018
Leukemia Antibodies CPX-351 Enasidenib Gemtuzumab ozogamicin Midostaurin

Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous years of testing and our increasing understanding of the pathophysiology of this disease. This interview took place at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, in Lisbon, Portugal.

More from Richard Stone

Evaluating the use of MRD status to guide post-remission therapy in AML
1:20
Evaluating the use of MRD status to guide post-remission therapy in AML
Richard Stone • 28 Feb 2026
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
1:40
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
Richard Stone • 28 Feb 2026
Approaches to managing FLT3-mutant AML
12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Novel targets, treatments, and combinations in AML
Novel targets, treatments, and combinations in AML
David Sallman et al. • 29 Sep 2022

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals